Eli Lilly and Co. said foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs.
from WSJ.com: US Business http://ift.tt/1veacIg
via IFTTT
from WSJ.com: US Business http://ift.tt/1veacIg
via IFTTT
No comments:
Post a Comment